Making Sense of Composite Endpoints in Clinical Research
Journal of Clinical Medicine · 29.06.2023 · 12 (13) · 4371
DOI: 10.3390/jcm12134371 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 29.06.2023. Verfasst von Daniela Baracaldo-Santamaría und 5 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacology Unit, Department of Biomedical Sciences, School of Medicine and Health Sciences, Universidad del Rosario, Bogotá 111221, Colombia. Die Arbeit wurde bisher 63-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bayer S.A. Colombia, Universidad del Rosario.
Abstract (Originalsprache)
Multiple drugs currently used in clinical practice have been approved by regulatory agencies based on studies that utilize composite endpoints. Composite endpoints are appealing because they reduce sample size requirements, follow-up periods, and costs. However, interpreting composite endpoints can be challenging, and their misuse is not uncommon. Incorrect interpretation of composite outcomes can lead to misleading conclusions that impact patient care. To correctly interpret composite outcomes, several important questions should be considered. Are the individual components of the composite outcome equally important to patients? Did the more and less important endpoints occur with similar frequency? Do the component endpoints exhibit similar relative risk reductions? If these questions receive affirmative answers, the use and interpretation of the composite endpoint would be appropriate. However, if any component of the composite endpoint fails to satisfy the aforementioned criteria, interpretation can become difficult, necessitating additional steps. Regulatory agencies acknowledge these challenges and have specific considerations when approving drugs based on studies employing composite endpoints. In conclusion, composite endpoints are valuable tools for evaluating the efficacy and net clinical benefit of interventions; however, cautious interpretation is advised.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pharmacology Unit, Department of Biomedical Sciences, School of Medicine and Health Sciences, Universidad del Rosario, Bogotá 111221, Colombia.
- School of Medicine, Universidad El Bosque, Bogotá 110121, Colombia.
- School of Medicine and Health Sciences, Universidad del Rosario, Bogotá 111221, Colombia.
- Research Group in Applied Biomedical Sciences (UR Biomed), School of Medicine and Health Sciences, Universidad del Rosario, Bogotá 111221, Colombia.
ORCID-Profile: Daniela Baracaldo-Santamaría, Luis Carlos Rojas-Rodríguez, Carlos Alberto Calderon-Ospina
Förderung
- Bayer S.A. Colombia
- Universidad del Rosario
Zitieren
APA
Baracaldo-Santamaría, D., Feliciano-Alfonso, J. E., Ramirez-Grueso, R., Rojas-Rodríguez, L. C., Dominguez-Dominguez, C. A., & Calderon-Ospina, C. A. (2023). Making Sense of Composite Endpoints in Clinical Research. Journal of Clinical Medicine, 12(13), 4371. https://doi.org/10.3390/jcm12134371
Vancouver
Baracaldo-Santamaría D, Feliciano-Alfonso JE, Ramirez-Grueso R, Rojas-Rodríguez LC, Dominguez-Dominguez CA, Calderon-Ospina CA. Making Sense of Composite Endpoints in Clinical Research. Journal of Clinical Medicine. 2023;12(13):4371. doi:10.3390/jcm12134371
BibTeX
@article{BaracaldoSantamara2023,
author = {Baracaldo-Santamaría, Daniela and Feliciano-Alfonso, John Edwin and Ramirez-Grueso, Raul and Rojas-Rodríguez, Luis Carlos and Dominguez-Dominguez, Camilo Alberto and Calderon-Ospina, Carlos Alberto},
title = {Making Sense of Composite Endpoints in Clinical Research},
journal = {Journal of Clinical Medicine},
year = {2023},
volume = {12},
number = {13},
pages = {4371},
doi = {10.3390/jcm12134371}
}
EUVIMED